Aditxt, Inc. Common Stock (ADTX)
Aditxt, Inc. (ADTX) is a biotechnology company focused on developing solutions to monitor, improve, and extend the health of the immune system. The company leverages its proprietary AditxtScore platform to assess immune system health and has interests in vaccine development and immunology research. Aditxt aims to address immune-related health issues through innovative technologies and therapies.
Company News
Evofem Biosciences launched a provocative "Say Vagina" campaign in August 2025, generating over 2.5 million social media views and increasing website traffic by 130%, aimed at normalizing medical terminology and women's health discussions.
Evofem Biosciences reported Q2 2025 financial results with 16% revenue growth to $4.8 million, driven by SOLOSEC acquisition and PHEXXI price adjustment. Despite operational improvements, the company experienced a net loss of $1.8 million and faces liquidity challenges ahead of a pending merger with Aditxt.
Appili Therapeutics announced its fiscal year 2025 results, highlighting the re-launch of LIKMEZ metronidazole oral suspension, progress on its tularemia vaccine candidate ATI-1701, and a topical antiparasitic product ATI-1801. The company submitted five U.S. government funding proposals totaling up to $125 million and reported a net loss of $2.6 million.
Indivior PLC (INDV) delivered earnings and revenue surprises of 13.33% and 2.26%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?